Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus® (ocrelizumab) data and continued [...]
Labeling updates to Ocrevus (ocrelizumab) injection, for intravenous use for the treatment of multiple sclerosis (MS) will be [...]
Janssen Pharmaceuticals recently published their sixth annual Janssen U.S. Transparency Report. The Report explains Janssen’s sustained [...]
Genentech is very excited to kick off #MSVisibility 2022 this coming Monday, March 28th with the launch of a new, bilingual video, focusing [...]
I’m pleased to share with you Sanofi’s 2022 Annual Pricing Principles report. This is the sixth consecutive edition of this [...]
Magnetic resonance spectroscopic imaging (MRSI) performed at 7.0 T (7.0-T MRSI) could visualize pathologic findings of multiple sclerosis [...]
TG Therapeutics has applied to the U.S. Food and Drug Administration (FDA) for approval of ublituximab, the company’s investigational [...]
NeurologyLive® Announces the Inaugural Giants of Multiple Sclerosis™ Program The first annual award program will honor [...]
The CMSC and IOMSN are proud to announce the following: Dr. Howard L. Weiner has just written a new book on brain diseases called The [...]
Consortium of Multiple Sclerosis Centers (CMSC) and Atara Biotherapeutics on Thursday - June 10, 2021 at 7:00 PM - 8:00 PM ETÂ on an [...]